ADMA Biologics Inc (ADMA)
Debt-to-capital ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | 72,337 | 130,594 | 142,833 | 94,866 | 92,969 |
Total stockholders’ equity | US$ in thousands | 349,018 | 135,206 | 151,974 | 141,173 | 88,249 |
Debt-to-capital ratio | 0.17 | 0.49 | 0.48 | 0.40 | 0.51 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $72,337K ÷ ($72,337K + $349,018K)
= 0.17
The Debt-to-Capital ratio for ADMA Biologics Inc has shown fluctuations over the past five years. Starting at 0.51 in December 2020, the ratio decreased to 0.40 by December 2021, indicating a lower reliance on debt in the company's capital structure. However, the ratio increased to 0.48 in December 2022 and further to 0.49 in December 2023, suggesting a higher proportion of debt in the capital mix. Notably, there was a significant decrease in the ratio to 0.17 by December 2024, signifying a potential reduction in debt relative to the company's overall capital. Overall, monitoring this metric is crucial in understanding ADMA Biologics Inc's leverage and financial risk management strategies.
Peer comparison
Dec 31, 2024